☆ 4.5 Review

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases

CURRENT ISSUES IN MOLECULAR BIOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients

Eric J. Lehrer et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Review Oncology

The role of immunotherapy in non-clear cell renal cell carcinoma

Carla Climent et al.

Summary: The category of non-clear cell renal cell carcinoma (nccRCC) includes diverse entities with different clinical, histological, and molecular characteristics. Traditional treatments for advanced clear cell RCC (ccRCC) show poorer outcomes in nccRCC patients, highlighting the need for more effective therapies. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown survival benefits in various cancers, including ccRCC, but clinical trials have not specifically studied nccRCC populations. This article reviews available trial data to identify clinical and molecular profiles that may benefit from immunotherapy approaches.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature

Qing-Wei Cheng et al.

Summary: This case report describes a patient with advanced renal cell carcinoma (RCC) who developed a pulmonary infection after treatment with everolimus in combination with lenvatinib. Next-generation sequencing (NGS) of bronchoscopic alveolar lavage fluid (BALF) identified the pathogenic organism as Pneumocystis jirovecii, and the infection was successfully treated with trimethoprim-sulfamethoxazole.

WORLD JOURNAL OF CLINICAL CASES (2023)

添加到收藏夹

Article Oncology

Management of Brain Metastases in Metastatic Renal Cell Carcinoma

Elshad Hasanov et al.

Summary: Despite improvements in overall survival, brain metastasis remains a poor prognostic feature in mRCC. Monitoring with brain MRIs is necessary for asymptomatic diagnosis. Treating active brain metastasis involves CNS-targeted therapy, with surgery or SRS depending on factors like lesion size, location, and neurological symptoms. SRS is increasingly preferred for multiple metastases. Systemic therapy follows CNS-targeted radiation or surgery. Ongoing studies aim to understand disease biology and find more effective treatments that prevent intracranial disease progression while addressing extracranial disease.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2023)

添加到收藏夹

Article Oncology

Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Kosuke Takemura et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Cristina Suarez et al.

Summary: This study investigated the efficacy of combining savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor) in metastatic papillary renal cancer. The results showed that the combination treatment could achieve high sustained response rate in the subset driven by MET.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer et al.

Summary: This is a phase 3 randomized trial evaluating the efficacy and safety of adjuvant nivolumab plus ipilimumab versus placebo in patients with resected localised renal cell carcinoma. The results showed that adjuvant therapy with nivolumab plus ipilimumab did not improve disease-free survival compared to placebo. This study does not support the use of this regimen as adjuvant treatment for renal cell carcinoma.

LANCET (2023)

添加到收藏夹

Review Oncology

The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature

Jole Ventriglia et al.

Summary: Non-clear cell renal cell carcinoma (nccRCC) accounts for 15-30% of renal tumors and is excluded from immunotherapy trials due to its rarity and worse prognosis. Reviewed data from various sources suggest that papillary and unclassified subtypes show good response rates to immunotherapy, while chromophobe cancers have null response rates. Sarcomatoid features predict good response to immunotherapy regardless of histology. However, data for other nccRCC subtypes are inconclusive. It is important to involve more nccRCC patients in clinical trials and report response rates and biomarker expression rates by subtypes to define the standard of treatment.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial & nbsp;

Laurence Albiges et al.

Summary: This study evaluated the activity and safety of pembrolizumab plus lenvatinib as a first-line treatment for advanced non-clear-cell renal cell carcinoma. The results showed that pembrolizumab plus lenvatinib has durable antitumor activity in these patients, with a safety profile consistent with previous studies. These findings support the use of pembrolizumab plus lenvatinib as a first-line treatment option for this patient population.

LANCET ONCOLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

Daniela Castro et al.

Summary: This study aimed to evaluate the restrictiveness of eligibility criteria in contemporary renal cell carcinoma trials and to use the recommendations from the ASCO-FCR initiative. The results showed that a significant proportion of RCC trials have restrictive eligibility criteria, excluding patients with prevalent comorbidities. Rating: 7/10.

BJU INTERNATIONAL (2023)

添加到收藏夹

Article Clinical Neurology

Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores

Shoji Yomo et al.

Summary: This study found that concurrent use of stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) for brain metastases (BMs) from renal cell carcinoma (RCC) prolonged overall survival (OS) and improved intracranial disease control without apparent increase in adverse events.

JOURNAL OF NEUROSURGERY (2023)

添加到收藏夹

Article Oncology

Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study

Eric J. Lehrer et al.

Summary: The occurrence of symptomatic radiation necrosis (RN) in patients with renal cell carcinoma (RCC) brain metastases treated with immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) is relatively low, with most events being grade 1 to 3 and managed by medical means. Concurrent therapy with ICI/SRS does not appear to increase the risk of RN. Efforts to improve dose conformality may be the most successful strategy for mitigating RN in single-fraction SRS.

CANCER (2022)

添加到收藏夹

Review Oncology

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

Bradley McGregor et al.

Summary: Tyrosine kinase inhibitors combined with immune checkpoint inhibitors have been effective in treating advanced renal cell carcinoma. However, the overlapping adverse events and immune-related adverse events can complicate treatment, necessitating proper management strategies to maintain tolerability.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam et al.

Summary: TelaE and TelaC showed promising clinical activity and tolerability in heavily pretreated metastatic renal cell carcinoma patients.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Urology & Nephrology

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

Jens Bedke et al.

Summary: Adjuvant pembrolizumab, an immune checkpoint inhibitor, showed significant improvement in disease-free survival (DFS) for high-risk clear cell renal cell carcinoma patients. However, the overall survival (OS) data are not yet available.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Cell Biology

Integrative clinical and molecular characterization of translocation renal cell carcinoma

Ziad Bakouny et al.

Summary: This study comprehensively defines the clinical and molecular features of translocation renal cell carcinoma (tRCC), a subtype of kidney cancer driven by MiT/TFE gene fusions. tRCCs mainly harbor MiT/TFE fusions and homozygous deletions at chromosome 9p21.3, and display a heightened NRF2-driven antioxidant response. Patients with tRCC treated with vascular endothelial growth factor receptor inhibitors (VEGFR-TKIs) have worse outcomes compared to those treated with immune checkpoint inhibitors (ICI). The study findings may inspire new therapeutic hypotheses for tRCC.

CELL REPORTS (2022)

添加到收藏夹

Review Oncology

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review

Chih-Hung Hsu et al.

Summary: AXL and MET play key roles in the progression, treatment resistance, and immunomodulation of HCC. Continued development of drugs that target these receptor tyrosine kinases appears likely to represent a useful strategy to improve outcomes for patients with HCC.

LIVER CANCER (2022)

添加到收藏夹

Editorial Material Oncology

Update on the treatment of metastatic renal cell carcinoma

Rafael Antonio Medina Lopez et al.

Summary: Management of metastatic renal cell cancer has undergone paradigm shifts with the emergence of vascular endothelial growth factor inhibitors and checkpoint inhibitors, as well as the combination of these strategies. However, questions regarding treatment comparisons, sequencing, non-clear cell mRCC, and the role of biomarkers still need to be addressed.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee et al.

Summary: The study results demonstrate that TelaE showed improved progression-free survival compared to PboE in patients with mRCC who had previously received treatment with VGEFR-targeted tyrosine kinase inhibitors and checkpoint inhibitors.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Global management of brain metastasis from renal cell carcinoma

Julien Pierrard et al.

Summary: In the past decade, significant progress has been made in the treatment of renal cell carcinoma with the development and use of various drugs. However, the management of brain metastases in RCC patients remains challenging. Local intervention and systemic therapies have limitations in treating cerebral lesions.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

Borje Ljungberg et al.

Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Editorial Material Urology & Nephrology

Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates

Yunze Xu et al.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Scott S. Tykodi et al.

Summary: The study evaluated the safety and efficacy of nivolumab plus ipilimumab in previously untreated advanced non-clear cell renal cell carcinoma (nccRCC) patients, showing a partial response rate of 19.6%, a median progression-free survival of 3.7 months, and a median overall survival of 21.2 months.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Urology & Nephrology

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma

Muhammad Ali et al.

Summary: Stereotactic ablative body radiotherapy (SABR) is a promising treatment modality for primary and metastatic renal cell carcinoma (RCC), offering potential benefits in terms of local control and delaying systemic therapy. It can be safely combined with systemic therapy and provides palliation for brain and spinal metastases.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

W. Kimryn Rathmell et al.

Summary: The article provides recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC), including diagnosis, treatment, and participation in clinical trials.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning

Zhixun Bai et al.

Summary: This study aimed to identify prognostic LncRNAs related to cuproptosis and construct a prognostic model using machine learning. The model was validated in the ICGC database and multiple renal cancer cell lines, showing its effectiveness.

BIOMOLECULES (2022)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta Kumar Pal et al.

Summary: The objective of this study was to determine if adjuvant atezolizumab delayed recurrence in renal cell carcinoma patients with an increased risk of recurrence. The study found that adjuvant atezolizumab did not improve clinical outcomes in patients with renal cell carcinoma.

LANCET (2022)

添加到收藏夹

Article Oncology

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma The CANTATA Randomized Clinical Trial

Nizar M. Tannir et al.

Summary: The study compared the efficacy and safety of telaglenastat plus cabozantinib with placebo plus cabozantinib in patients with advanced renal cell carcinoma. The results showed that telaglenastat did not improve the efficacy of cabozantinib, with no significant differences in progression-free survival and overall response rates between the two groups. The safety profiles were also similar.

JAMA ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

M. Allaf et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Chung-Han Lee et al.

Summary: Cabozantinib/nivolumab combination therapy shows promising efficacy in non-clear-cell renal cell carcinoma, particularly in variants with prominent papillary features, while the treatment effect is limited in chromophobe RCC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis

Masoumeh Najafi et al.

Summary: The combination of immuno/radiotherapy (IR) for the treatment of brain metastases from melanoma and non-small-cell lung carcinoma has prolonged overall survival and reduced mortality rate, with acceptable toxicity.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma The CANTATA Randomized Clinical Trial

Nizar M. Tannir et al.

Summary: In this randomized clinical trial, telaglenastat did not improve the efficacy of cabozantinib in metastatic RCC. The progression-free survival and overall response rates between the Tela + Cabo and Pbo + Cabo groups were similar. The rates of treatment-emergent adverse events were also similar between the two groups.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

T. Powles et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Ciro Franzese et al.

Summary: The study suggests that SBRT may play a significant role in oligometastatic kidney cancer settings, providing effective and safe options in multidisciplinary management for both oligorecurrent and oligoprogressive metastases.

CLINICAL & EXPERIMENTAL METASTASIS (2021)

添加到收藏夹

Review Immunology

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases

Vincenzo Di Nunno et al.

Summary: Immune checkpoint inhibitors show potential in the treatment of brain metastases, particularly for melanoma. The clinical role of immune checkpoint inhibitors for brain metastases from other solid malignancies remains uncertain at present.

IMMUNOTHERAPY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Belzutifan: First Approval

Emma D. Deeks

Summary: Belzutifan is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2 alpha, developed by Peloton Therapeutics for the treatment of solid tumors, including renal cell carcinoma (RCC) and von Hippel-Lindau (VHL) disease-associated RCC. It has received its first approval in the USA for the treatment of VHL disease patients requiring therapy for associated tumors, with clinical studies ongoing in other indications.

DRUGS (2021)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

Shaan Dudani et al.

Summary: This study found that patterns of metastasis vary between histologic subtypes of metastatic RCC and are associated with overall survival. The data highlight the clinical and biological variability between histologic subtypes and suggest that patterns of metastasis may reflect differences in underlying disease biology. Further research is encouraged to investigate differences in immune, molecular, and genetic profiles between metastatic sites and histologic subtypes.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Oncology

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

Chad Tang et al.

Summary: This study investigated the feasibility and efficacy of radiotherapy to postpone systemic therapy for patients with oligometastatic renal cell carcinoma. Results showed that radiotherapy could defer systemic therapy initiation for select patients and allow sustained systemic therapy breaks, with good tolerance.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease

Eric Jonasch et al.

Summary: The HIF-2α inhibitor belzutifan showed efficacy in patients with renal cell carcinoma associated with von Hippel-Lindau disease, with nearly half of the patients having an objective response to treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

David F. McDermott et al.

Summary: First-line pembrolizumab monotherapy demonstrated promising antitumor activity in patients with nccRCC, showing similar efficacy and safety profile to other tumor types.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal et al.

Summary: In this study comparing different drug treatments for papillary renal cell carcinoma, cabozantinib was found to result in significantly longer progression-free survival compared to sunitinib, while savolitinib and crizotinib did not show an improvement in progression-free survival.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Matthew T. Campbell et al.

Summary: In this pilot study of anti-CTLA-4 therapy with or without cryoablation in metastatic renal cell carcinoma patients, the combination is shown to be feasible and enhances immune cell infiltration in patients with metastatic clear cell histology. The findings highlight the potential of combining tremelimumab with cryotherapy to modulate the immune microenvironment in patients with metastatic clear cell histology to improve anti-tumor immune responses.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Urology & Nephrology

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

Thomas E. Hutson et al.

Summary: The combination of lenvatinib plus everolimus as a first-line treatment showed promising anticancer activity for patients with advanced non-clear cell renal cell carcinoma, with a relatively high objective response rate and manageable treatment-related adverse events.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Florent Peyraud et al.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma

Elshad Hasanov et al.

Summary: Von Hippel-Lindau (VHL) disease is a genetic syndrome caused by mutations in the VHL gene, resulting in tumors and cysts in multiple organs. Surgery is the standard treatment for localized tumors, but repeated surgeries lead to significant morbidity. MK-6482, a small-molecule HIF 2 alpha inhibitor, has shown promising efficacy and safety in VHL disease-related tumors.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Review Oncology

The abscopal effect of radiation therapy

Daniel J. Craig et al.

Summary: Radiation therapy can induce a systemic anticancer response by promoting immune activation. Enhancing T-cell activity through immunotherapeutic drugs can further augment this effect. The presence of tumor infiltrating lymphocytes and specific signal expression may serve as prognostic biomarkers.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma

Laure Hirsch et al.

Summary: This study evaluated the clinical activity and toxic effects of cabozantinib for treating brain metastases in patients with metastatic renal cell carcinoma. The findings showed significant intracranial activity and an acceptable safety profile of cabozantinib in these patients, highlighting the need for further prospective studies to assess its efficacy.

JAMA ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Tracking Cancer Evolution through the Disease Course

Chris Bailey et al.

Summary: TRACERx studies focus on tracking cancer evolution in a clinical setting, from primary disease to recurrence. Through multiregion and longitudinal sampling, TRACERx has detailed the evolutionary processes in tumor and immune microenvironment in non-small cell lung cancer and clear-cell renal cell carcinoma, revealing the therapeutic potential of targeting clonal neoantigens and ctDNA detection in the adjuvant setting.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic for Renal Cell Carcinoma

Zeynep B. Zengin et al.

Summary: This study explores the role of circulating cell-free tumor DNA as an adjunct to tissue genomic profiling in metastic renal cell carcinoma (mRCC), confirming the feasibility and potential of using ctDNA to identify actionable alterations. The study also reveals that ctDNA and tissue-based genomic profiling are complementary, with unique alterations identified by both platforms, and the frequency of unique alterations increases with greater temporal separation between tests.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Oncology

Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors

Lorena Incorvaia et al.

Summary: The introduction of ICIs in RCC treatment landscape has improved overall survival in metastatic patients, but treating patients with brain metastases remains a challenge. Immunotherapy responsiveness is multifactorial and dependent on factors such as genetic intratumor heterogeneity and the immunosuppressive role of the brain tumor microenvironment.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

Chun L. Gan et al.

Summary: This study compared the outcomes of trial-ineligible vs.-eligible patients with advanced solid tumors treated with first-line IO therapy, revealing that trial-ineligible patients had significantly lower overall survival, overall response rate, treatment duration, and time to next treatment compared to trial-eligible patients.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Urology & Nephrology

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

Patrick Cheung et al.

Summary: SRT for oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients on tyrosine kinase inhibitor (TKI) therapy showed high local control (LC) and delayed the need to change systemic therapy.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Sumanta K. Pal et al.

Summary: The study showed that the combination of cabozantinib plus atezolizumab has promising clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

Pierangela Sepe et al.

Summary: Non-clear cell renal cell carcinomas (ncRCC) are rare and lack standard treatments, with choices based on extrapolating results from clear cell RCC trials; the emergence of immunotherapy and new targeted drugs provides more diverse treatment options for the future.

CANCERS (2021)

添加到收藏夹

Article Oncology

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)

Marco Stellato et al.

Summary: Patients with previous nephrectomy treated with IO had better OS outcomes. Gland metastases were also associated with improved OS and PFS outcomes.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors

Wei Du et al.

Summary: Brain metastases (BM) have a poor prognosis, and treatment with immune checkpoint inhibitors (ICIs) improves survival in patients with BM from non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and melanoma, but not in renal cell carcinoma (RCC) patients. Further research is needed to identify prognostic features, oncogenomic profiles, and predictive biomarkers.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma

Ethan Emberley et al.

Summary: Dysregulated metabolism is a hallmark of cancer, with renal cell carcinoma cells showing high dependence on glutamine for proliferation and sensitivity to the GLS inhibitor telaglenastat. Combining signal transduction inhibitors with telaglenastat significantly decreases glucose and glutamine consumption, leading to synergistic anti-proliferative effects. The combination of telaglenastat with cabozantinib or everolimus demonstrates potent, synergistic anti-tumor activity through dual inhibition of glucose and glutamine consumption.

PLOS ONE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Lei Zhong et al.

Summary: Targeted therapeutic drugs have become mainstream cancer treatments due to their advantages in efficacy and safety, but still face challenges such as low response rate and drug resistance. A comprehensive review was conducted on small-molecule targeted anti-cancer drugs to promote their development, discussing current challenges and providing insights and perspectives for future research and development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Urology & Nephrology

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Charles Van Praet et al.

Summary: This study provides an overview of the history of cytoreductive nephrectomy, analyses of the SURTIME and CARMENA trials, and current indications for immediate or deferred CN.

TURKISH JOURNAL OF UROLOGY (2021)

添加到收藏夹

Article Oncology

Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis

Jad Chahoud et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

Bradley A. McGregor et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma

Ruby Gupta et al.

CLINICAL GENITOURINARY CANCER (2020)

添加到收藏夹

Review Oncology

An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)

Alberto D'Angelo et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Neurologic complications of immune checkpoint inhibitors

Alexandra M. Haugh et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Article Oncology

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001

Paul D. Brown et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials

Sarah E. Wong et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

添加到收藏夹

Article Oncology

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Nicholas J. Vogelzang et al.

CLINICAL GENITOURINARY CANCER (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Antoine Deleuze et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Oncology

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

Michael B. Atkins et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Zhilin Zou et al.

CELL AND BIOSCIENCE (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes

Junyi Hu et al.

MOLECULAR THERAPY (2020)

添加到收藏夹

Article Oncology

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial

Toni K. Choueiri et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Immunology

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

Andrea Botticelli et al.

VACCINES (2020)

添加到收藏夹

Article Oncology

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Joshua J. McFarlane et al.

CLINICAL GENITOURINARY CANCER (2020)

添加到收藏夹

Article Oncology

Les cancers du rein non à cellules claires : caractéristiques clinico-biologiques et prise en charge thérapeutique hors chirurgie

Jonathan Thouvenin et al.

BULLETIN DU CANCER (2020)

添加到收藏夹

Review Immunology

Abscopal effect in radioimmunotherapy

Milad Ashrafizadeh et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Review Oncology

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma

Muhammad Khan et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing

Z. B. Zengin et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study

S. Pal et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Urology & Nephrology

Genomic profiling in renal cell carcinoma

Nazli Dizman et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Review Urology & Nephrology

The immunology of renal cell carcinoma

C. Marcela Diaz-Montero et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors

J. Tanner McMahon et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)

添加到收藏夹

Article Urology & Nephrology

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Yasser Ged et al.

BMC UROLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting the HIF2-VEGF axis in renal cell carcinoma

Toni K. Choueiri et al.

NATURE MEDICINE (2020)

添加到收藏夹

Review Oncology

Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

Yoshiyuki Matsui

CANCERS (2020)

添加到收藏夹

Article Oncology

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

Rana R. McKay et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Health Care Sciences & Services

Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations

Amelia J. Averitt et al.

NPJ DIGITAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data

Roderick de Bruijn et al.

EUROPEAN UROLOGY ONCOLOGY (2020)

添加到收藏夹

Review Oncology

The role of brachytherapy in the management of brain metastases: a systematic review

Bhargava Chitti et al.

JOURNAL OF CONTEMPORARY BRACHYTHERAPY (2020)

添加到收藏夹

Review Oncology

The blood-brain barrier and blood-tumour barrier in brain tumours and metastases

Costas D. Arvanitis et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Review Urology & Nephrology

Epidemiology of Renal Cell Carcinoma

Umberto Capitanio et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Oncology

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Nieves Martinez Changa et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

Giorgia Peverelli et al.

CLINICAL GENITOURINARY CANCER (2019)

添加到收藏夹

Article Oncology

Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World

S. Karim et al.

CLINICAL ONCOLOGY (2019)

添加到收藏夹

Editorial Material Oncology

Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous

Jarred P. Reed et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Ronan Flippot et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Editorial Material Oncology

Immune-checkpoint inhibitors in brain metastases from renal cell carcinoma: a battle was lost but not the war

Giuseppe Lombardi et al.

ANNALS OF TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Review Oncology

Leptomeningeal Metastases in Renal Cell Carcinoma at Initial Diagnosis: 2 Case Reports and Literature Review

Manel Dridi et al.

CANCER INVESTIGATION (2019)

添加到收藏夹

Article Medicine, Research & Experimental

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

Brian W. Labadie et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Chenjing Zhu et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Review Clinical Neurology

Complications associated with immunotherapy for brain metastases

Thuy T. Tran et al.

CURRENT OPINION IN NEUROLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Brain metastases

Achal Singh Achrol et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

添加到收藏夹

Article Oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial

Axel Bex et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Editorial Material Oncology

Management of brain metastases from renal cell carcinoma

Suguru Shirotake

ANNALS OF TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Review Oncology

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors

Katherine Emilie Rhoades Smith et al.

KIDNEY CANCER (2019)

添加到收藏夹

Review Oncology

Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature

Chiara Ciccarese et al.

CLINICAL GENITOURINARY CANCER (2018)

添加到收藏夹

Article Urology & Nephrology

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling

Sumanta K. Pal et al.

EUROPEAN UROLOGY (2018)

添加到收藏夹

Article Oncology

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program

Sergio Bracarda et al.

FUTURE ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Linda Chen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

Yazhuo Zhang et al.

MOLECULAR CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

A. Mejean et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer

Manmeet S. Ahluwalia et al.

ONCOLOGIST (2018)

添加到收藏夹

Review Urology & Nephrology

Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management

Eamonn R. Maher

WORLD JOURNAL OF UROLOGY (2018)

添加到收藏夹

Review Oncology

A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin

Joseph Kattan et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)

添加到收藏夹

Review Clinical Neurology

Management of Brain Metastases in the New Era of Checkpoint Inhibition

Adam Lauko et al.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)

添加到收藏夹

Article Neurosciences

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Claudia Brandt et al.

NEUROPHARMACOLOGY (2018)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

A. Boileve et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Urology & Nephrology

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study

Amishi Y. Shah et al.

BJU INTERNATIONAL (2017)

添加到收藏夹

Review Oncology

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

I. Duran et al.

TARGETED ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Patrick Schoffski et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Review Urology & Nephrology

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma

Sergio Fernandez-Pello et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Review Urology & Nephrology

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

Maud Rijnders et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Article Oncology

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

Aly-Khan A. Lalani et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review

Bum Jun Kim et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model

Jianlong Tan et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Naomi B. Haas et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma The ARISER Randomized Clinical Trial

Karim Chamie et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era The University of Rochester Experience

James E. Bates et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)

添加到收藏夹

Review Oncology

The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review

Candice Schwartz et al.

CLINICAL GENITOURINARY CANCER (2017)

添加到收藏夹

Article Oncology

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma

Nicolas A. Giraldo et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Challenging Populations

Douglas B. Johnson et al.

CANCER (2017)

添加到收藏夹

Article Oncology

Cabozantinib: Mechanism of action, efficacy and indications

Valerie Cochin et al.

BULLETIN DU CANCER (2017)

添加到收藏夹

Review Oncology

Tumor microenvironment and therapeutic response

Ting Wu et al.

CANCER LETTERS (2017)

添加到收藏夹

Article Urology & Nephrology

Renal cell cancer histological subtype distribution differs by race and sex

Loren Lipworth et al.

BJU INTERNATIONAL (2016)

添加到收藏夹

Review Engineering, Biomedical

Renal cell carcinoma: Review of etiology, pathophysiology and risk factors

Nadezda Petejova et al.

BIOMEDICAL PAPERS-OLOMOUC (2016)

添加到收藏夹

Article Medicine, General & Internal

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy

Yan Song et al.

CHINESE MEDICAL JOURNAL (2016)

添加到收藏夹

Review Oncology

Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis

Fausto Petrelli et al.

CLINICAL GENITOURINARY CANCER (2016)

添加到收藏夹

Article Urology & Nephrology

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir et al.

EUROPEAN UROLOGY (2016)

添加到收藏夹

Article Oncology

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Martin H. Voss et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Andrew J. Armstrong et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

W. Marston Linehan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Cell Biology

Clinical trial of blood-brain barrier disruption by pulsed ultrasound

Alexandre Carpentier et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Article Chemistry, Medicinal

Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity

Shuai Jiang et al.

CHEMICAL RESEARCH IN TOXICOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Urology & Nephrology

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Romain Mathieu et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker

Florentina Serban et al.

ONCOTARGETS AND THERAPY (2015)

添加到收藏夹

Article Oncology

Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era

Dalsan You et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

Paul R. Gavine et al.

MOLECULAR ONCOLOGY (2015)

添加到收藏夹

Review Urology & Nephrology

Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma

Daniele Alesini et al.

THERAPEUTIC ADVANCES IN UROLOGY (2015)

添加到收藏夹

Review Oncology

VHL, the story of a tumour suppressor gene

Lucy Gossage et al.

NATURE REVIEWS CANCER (2015)

添加到收藏夹

Article Oncology

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

D. Y. C. Heng et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

Caleb F. Davis et al.

CANCER CELL (2014)

添加到收藏夹

Article Oncology

MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

Laurence Albiges et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

Fred H. Menko et al.

FAMILIAL CANCER (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

Mohammad Hojjat-Farsangi

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)

添加到收藏夹

Review Oncology

PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+breast cancer

Parvin F. Peddi et al.

JOURNAL OF NEURO-ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma

N. Pecuchet et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

Arkadiusz Z. Dudek et al.

CLINICAL GENITOURINARY CANCER (2013)

添加到收藏夹

Article Oncology

Diagnosis and management of BHD-associated kidney cancer

Lambros Stamatakis et al.

FAMILIAL CANCER (2013)

添加到收藏夹

Article Oncology

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Cell Biology

Central Role of RET in Thyroid Cancer

Massimo Santoro et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)

添加到收藏夹

Article Oncology

Loss of VHL in RCC reduces repair and alters cellular response to benzo[a]pyrene

Marten A. Schults et al.

FRONTIERS IN ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

J. -L. Lee et al.

ANNALS OF ONCOLOGY (2012)

添加到收藏夹

Article Oncology

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models

Hong Zhao et al.

BREAST CANCER RESEARCH AND TREATMENT (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms

Lucieli Ceolin et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)

添加到收藏夹

Review Oncology

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

Roger B. Cohen et al.

INVESTIGATIONAL NEW DRUGS (2012)

添加到收藏夹

Article Oncology

Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases

Martin E. Gore et al.

CANCER (2011)

添加到收藏夹

Article Urology & Nephrology

Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: Our experience and review of the literature

Yuji Kusuda et al.

INTERNATIONAL JOURNAL OF UROLOGY (2011)

添加到收藏夹

Article Oncology

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes et al.

MOLECULAR CANCER THERAPEUTICS (2011)

添加到收藏夹

Article Urology & Nephrology

Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC

Toshinari Yamasaki et al.

NATURE REVIEWS UROLOGY (2011)

添加到收藏夹

Review Peripheral Vascular Disease

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Kristy J. Gotink et al.

ANGIOGENESIS (2010)

添加到收藏夹

Article Oncology

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

G. G. Malouf et al.

ANNALS OF ONCOLOGY (2010)

添加到收藏夹

Article Urology & Nephrology

Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy

Edward M. Schaeffer et al.

BJU INTERNATIONAL (2010)

添加到收藏夹

Article Oncology

Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma

Toni K. Choueiri et al.

CANCER (2010)

添加到收藏夹

Article Peripheral Vascular Disease

Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage

Carrie Anna Geisberg et al.

CURRENT HYPERTENSION REPORTS (2010)

添加到收藏夹

Review Pharmacology & Pharmacy

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

Rachel Ma Linger et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2010)

添加到收藏夹

Review Oncology

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?

Robert Goldstein et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2010)

添加到收藏夹

Article Neurosciences

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Jonathan H. Fox et al.

MOLECULAR NEURODEGENERATION (2010)

添加到收藏夹

Article Oncology

Complete Response to Carboplatin, Gemcitabine, and Paclitaxel in a Patient With Advanced Metastatic Renal Medullary Carcinoma

Alexandra Walsh et al.

PEDIATRIC BLOOD & CANCER (2010)

添加到收藏夹

Article Oncology

Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole-Brain Radiotherapy Be Added to Stereotactic Radiosurgery? Analysis of 88 Patients

Emmanouil Fokas et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2010)

添加到收藏夹

Article Oncology

Targeting the RET Pathway in Thyroid Cancer

Samuel A. Wells et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Article Clinical Neurology

CYBERKNIFE FOR BRAIN METASTASES OF MALIGNANT MELANOMA AND RENAL CELL CARCINOMA

Wendy Hara et al.

NEUROSURGERY (2009)

添加到收藏夹

Article Oncology

Multidisciplinary Treatment of Brain Metastases Derived From Clear Cell Renal Cancer Incorporating Stereotactic Radiosurgery

Wolfram E. Samlowski et al.

CANCER (2008)

添加到收藏夹

Article Oncology

Familial non-VHL clear cell (conventional) renal cell carcinoma:: Clinical features, segregation analysis, and mutation analysis of FLCN

Emma R. Woodward et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹

Article Oncology

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Meeting Abstract Oncology

Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC)

T. K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Oncology

An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

Helen Y. Zou et al.

CANCER RESEARCH (2007)

添加到收藏夹

Article Urology & Nephrology

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: Results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study

Setphane Oudard et al.

JOURNAL OF UROLOGY (2007)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Molecular basis for sunitinib efficacy and future clinical development

Sandrine Faivre et al.

NATURE REVIEWS DRUG DISCOVERY (2007)

添加到收藏夹

Review Oncology

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

BI Rini et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

Article Oncology

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

GV Kondagunta et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

添加到收藏夹

Article Oncology

Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: A retrospective study

SB Cannady et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)

添加到收藏夹

Article Oncology

The role of chemotherapy in brain metastases

MJ van den Bent

EUROPEAN JOURNAL OF CANCER (2003)

添加到收藏夹

Article Pathology

Renal tumors in the Birt-Hogg-Dube syndrome

CP Pavlovich et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)

添加到收藏夹

Article Oncology

Active chemotherapy for collecting duct carcinoma of the kidney - A case report and review of the literature

MI Milowsky et al.

CANCER (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.